Company news

UroGen Pharma Ltd. news in 2026

UroGen Pharma Ltd.'s news releases, calls and decks from 2026, newest first.

View company

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights

November 4, 2026

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

November 3, 2026

UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

November 2, 2026

UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer

October 28, 2026

UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026

October 27, 2026

UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC

October 19, 2026

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

August 20, 2026

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

August 20, 2026

UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC

August 17, 2026

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

August 5, 2026

UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

July 29, 2026

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

July 15, 2026

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

July 8, 2026

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

June 8, 2026

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

June 1, 2026

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

June 1, 2026

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

May 15, 2026

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

May 6, 2026

UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026

April 28, 2026

UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer

April 7, 2026

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

March 30, 2026

UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence

March 13, 2026

UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

March 2, 2026

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors

March 1, 2026

ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC

February 27, 2026

UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026

February 23, 2026

UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit

February 3, 2026

Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy

January 4, 2026

Calls in 2026

Decks in 2026